^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WXSH0011

    i
    Other names: WXSH0011
    Company:
    WuXi AppTec
    Drug class:
    FGFR inhibitor, c-MET inhibitor
    Related drugs:
    over4years
    [VIRTUAL] Preclinical evaluation of WXSH0011, a selective small molecule dual inhibitor of FGFR/c-Met. (ASCO 2020)
    We have identified a novel selective and potent dual FGFR/c-Met inhibitor WXSH0011. Preclinical studies shows antitumor efficacy of WXSH0011 in gastric and liver cancer models. It is currently at IND submission stage.
    Preclinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • HGF (Hepatocyte growth factor) • FGF (Fibroblast Growth Factor)
    |
    MET overexpression • FGFR overexpression
    |
    WXSH0011